NOAC monotherapy reduces net adverse clinical events in older patients with atrial fibrillation and stents
NOAC Monotherapy Shows Lower Risk for Older Patients with Atrial Fibrillation
This post hoc analysis investigated the impact of NOAC monotherapy versus combination therapy with clopidogrel in patients with atrial fibri…
Patients over 75 with atrial fibrillation and drug-eluting stents may have fewer adverse events when taking a single NOAC instead of combina…
Left atrial appendage occlusion and NOACs reduce mortality compared with warfarin in atrial fibrillation
LAAO, low-dose NOACs beat warfarin for atrial fibrillation survival
A network meta-analysis compared left atrial appendage occlusion (LAAO), low-dose NOACs, standard-dose NOACs, and warfarin in non-valvular a…
For people with atrial fibrillation, warfarin may be the worst option for survival. New analysis finds LAAO and NOACs outperform it.
LAAC shows noninferior efficacy and reduced bleeding versus NOACs in non-valvular AF
New data shows left atrial appendage closure offers bleeding safety for some adults with atrial fibrillation
This meta-analysis of RCTs in adults with non-valvular AF found percutaneous left atrial appendage closure (LAAC) achieved noninferiority fo…
A large review of trials found that closing the heart appendage reduced bleeding compared to blood thinners. However, stroke risk trends wer…